90Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. a GELA phase II prospective study

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 2, 2011, Pages 212-218

  Decaudin, Didier ^a   Mounier, Nicolas ^b   Tilly, Hervé ^c   Ribrag, Vincent ^d   Ghesquières, Hervé ^e   Bouabdallah, Krimo ^f   Morschhauser, Franck ^g   Coiffier, Bertrand ^h   Le Gouill, Steven ⁱ   Bologna, Serge ^j   Delarue, Richard ^k   Huynh, Anne ^l   Bosly, André ^m   Brière, Josette ⁿ   Gisselbrecht, Christian ⁿ  

^a INSTITUT CURIE   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Centre Becquerel   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE LÉON BÉRARD   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l TOULOUSE UNIVERSITY HOSPITAL   (France)

^m UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁿ SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

90Y ibritumomab tiuxetan; BEAM regimen; Follicular lymphoma; Transplantation

Indexed keywords

ALPHA INTERFERON; ARABINOSIDE; CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; CARMUSTINE; MONOCLONAL ANTIBODY; PODOPHYLLOTOXIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CANDIDIASIS; CHEMOSENSITIVITY; CLOSTRIDIUM DIFFICILE INFECTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYSIPELAS; ERYTHEMA; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; HYPOPLASIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYELOMONOCYTIC LEUKEMIA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; QUADRIPLEGIA; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SALVAGE THERAPY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AUTOTRANSPLANTATION; CANCER STAGING; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; PODOPHYLLOTOXIN; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052840569     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.007     Document Type: Article

References (37)

1. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Eur J Nucl Med 27 2000 766 777 (Pubitemid 30456759)
2. T.E. Witzig, A. Molina, and L.I. Gordon Long-term responses in patients with recurring or refractory B-cell non-Hodgkin's lymphoma treated with yttrium 90 ibritumomab tiuxetan Cancer 109 2007 1804 1810 (Pubitemid 46668544)
3. F. Morschhauser, T. Illidge, and D. Huglo Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation Blood 110 2007 54 58 (Pubitemid 47026818)
4. T.E. Witzig, I.W. Flinn, and L.I. Gordon Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol 20 2002 3262 3269 (Pubitemid 34831524)
5. 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma Clin Cancer Res 14 2008 7088 7094
6. F. Morschhauser, J. Radford, and A. Van Hoof Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 2008 5156 5164
7. P.L. Zinzani, M. Tani, and A. Pulsoni Fludarabine and mitoxantrone followed by yttrium-90-ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin's lymphoma trial: a phase II non-randomised trial (FLUMIZ) Lancet Oncol 9 2008 352 358
8. P.L. Zinzani, M. Tani, and S. Fanti A phase II trial of CHOP chemotherapy followed by yttrium-90-ibritumomab tiuxetan for previously untreated elderly diffuse large B-cell lymphoma patients Ann Oncol 19 2008 769 773 (Pubitemid 351461050)
9. A. Nademanee, S. Forman, and A. Molina A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin's lymphoma Blood 106 2005 2856-302
10. J.M. Vose, P.J. Bierman, F.R. Loberiza Jr, R.G. Bociek, D. Matso, and J.O. Armitage Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation Leuk Lymphoma 48 2007 683 690 (Pubitemid 46605539)
11. A. Krishnan, A. Nademanee, and H.C. Fung Phase II trial of a transplantation regimen of Yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma J Clin Oncol 26 2008 90 95
12. 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas Br J Haematol 139 2007 590 599 (Pubitemid 350043818)
13. L. Devizzi, A. Guidetti, and C. Tarella High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation J Clin Oncol 26 2008 5175 5182
14. O.W. Press, J.F. Eary, and T. Gooley A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 96 2000 2934 2942
15. 90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma Bone Marrow Transplant 40 2007 1007 1017 (Pubitemid 350147685)
16. P.J. Bierman, J.M. Vose, and J.R. Anderson High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma J Clin Oncol 15 1997 445 450 (Pubitemid 27074210)
17. P. Brice, D. Simon, and R. Bouabdallah High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol Ann Oncol 11 2000 1585 1590 (Pubitemid 32104758)
18. H.C. Schouten, W. Qian, and S. Kvaloy High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial J Clin Oncol 21 2003 3918 3927 (Pubitemid 46606204)
19. C. Sebban, P. Brice, and R. Delarue Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study J Clin Oncol 26 2008 3614 3620
20. R. Forstpointner, M. Unterhalt, and M. Dreyling Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) Blood 108 2006 4003 4008 (Pubitemid 44920177)
21. M. Ghielmini, S.F. Schmitz, and S.B. Cogliatti Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule Blood 103 2004 4416 4423 (Pubitemid 38745964)
22. M.H. Van Oers, R. Klasa, and R.E. Marcus Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood 108 2006 3295 3301 (Pubitemid 44794222)
23. N.L. Harris, E.S. Jaffe, and J. Diébold World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997 J Clin Oncol 17 1999 3835 3849
24. B.D. Cheson, J.S. Horning, and B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol 17 1999 1244 1253 (Pubitemid 29162950)
25. M.M. Oken, R.H. Creech, and D.C. Tormay Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655 (Pubitemid 13149996)
26. Y. Bastion, P. Brice, and C. Haioun Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma Blood 86 1995 3257 3262
27. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
28. D.R. Cox Regression models and life tables J R Stat Soc [Ser A] 34 1972 187 220
29. S. Vignot, N. Mounier, and J. Larghero High-dose therapy and autologous stem-cell transplantation can improve event-free survival for indolent lymphoma: a study using patients as their own controls Cancer 109 2007 60 67 (Pubitemid 46127201)
30. N. Puig, J. de la Rubia, and M.J. Remigia Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation Leuk Lymphoma 47 2006 1488 1494 (Pubitemid 44364012)
31. W. Mills, R. Chopra, and A. McMillan BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma J Clin Oncol 13 1995 588 595
32. M.S. Czuczman, C. Emmanouilides, and M. Darif Treatment-related myelodysplastic syndrome and acute myelogenous leukaemia in patients treated with ibritumomab tiuxetan radioimmunotherapy J Clin Oncol 25 2007 4285 4292 (Pubitemid 47548569)
33. J.N. Winter, D.J. Inwards, and S. Spies Yttrium-90 Ibritumomab Tiuxetan doses calculated to deliver up to 15 Gy to critical organs may safely be combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 27 2009 1653 1659
34. S. Montoto, C. Canals, and A.Z.S. Rohatiner Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study for the EBMT Lymphoma Working Party Leukemia 21 2007 2324 2331 (Pubitemid 350011705)
35. A.K. Gopal, T.A. Gooley, and D.G. Maloney High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis Blood 102 2003 2351 2357 (Pubitemid 37193569)
36. M.T. Voso, S. Martin, and S. Hohaus Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT) Bone Marrow Transplant 25 2000 957 964 (Pubitemid 30255728)
37. C. Tarella, M. Zanni, and M. Magni Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey J Clin Oncol 26 2008 3166 3175